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Background/aim: Sarcopenia and dementia are growing concerns among older adults that muscle and brain atrophy may cooccur. We
aimed to compare the age-related loss of muscle mass by using ultrasound (US), and skeletal muscle mass index (SMI) by bioelectrical
impedance analysis in older adults with and without dementia.
Materials and methods: A total of 221 older adults aged ≥65 years were included in the study. The diagnosis of sarcopenia was
established if low muscle mass according to either SMI or sonographic gastrocnemius (GC) muscle thickness was combined with low
grip strength. The diagnosis of dementia was based on the National Institute of Aging and Alzheimer’s Association criteria and the major
neurocognitive disorder definition in the Diagnostic and Statistical Manual of Mental Disorders-V. Muscle strength was measured by
hand dynamometer and physical performance was assessed by 4-meter usual gait speed.
Results: There were similar/moderate correlation coefficients between GC muscle thickness and SMI with functional parameters (all p
< 0.01). Forty-six patients (20.8%) had dementia, and 21 (45.7%) of them had sarcopenia diagnosed by GC thickness (p < 0.001). Age
was older but weight, body mass index, and all sarcopenia-related parameters were lower in dementia patients (all p < 0.01). When
clinical variables were taken into binary logistic regression analyses, age [OR = 1.095 (95% CI: 1.028–1.167)], weight [OR = 0.918 (95%
CI: 0.887–0.950)], and presence of dementia [OR = 5.109 (95% CI: 2.002–13.033)] were independently associated with sarcopenia
diagnosed with GC muscle thickness (all p < 0.05).
Conclusion: This study showed that sarcopenia is highly prevalent in older adults with dementia (45.7%) than without dementia
(11.4%). Amongst different factors, increased age, having low body weight, and the presence of dementia independently increased
the risk of sarcopenia diagnosed by GC muscle thickness (but not diagnosed by SMI) in older adults. Thus, we can evaluate easily and
successfully the loss of (regional) muscle mass in dementia patients by using US in outpatient clinics.
Key words: Alzheimer’s disease, gastrocnemius, grip strength, muscle thickness, ultrasound

1. Introduction
Sarcopenia is an age-related progressive loss of muscle mass
and muscle function associated with adverse outcomes
from the increased risk of functional decline to early death
[1]. It can be defined as primary if it is due to only aging
process or secondary if it is due to other causes such as
comorbidities, malnutrition, or immobility. Among them,
cognitive dysfunction is one of the most common cause of
secondary sarcopenia by influencing the muscle function
and physical performance [2]. In this regard, studies
have indicated that sarcopenic patients are vulnerable
to developing cognitive impairment, and sarcopenia is
common among individuals with dementia [3,4].

Dementia is a neurodegenerative disease characterized
by the deterioration of cognitive functions. The most
common form of dementia is Alzheimer’s disease (AD),
and its earliest sign is memory loss, and patients become
dependent in daily life activities in the advanced stages
[5]. With an aging population and improvements in life
expectancy, the prevalence of dementia is expected to
increase [6]. Because of the disease burden on health care
expenditures, the researches on prevention and treatment
of the disease are crucial.
Sarcopenia and dementia share common pathologies
that as loss of lean mass has been associated with ADrelated brain atrophy [7]. Presentation of sarcopenia in
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these individuals may be due to the reduction in physical
activity levels that is both observed in those with dementia
and linked with reductions in gray matter volumes [8].
As a component of sarcopenia diagnosis there are
several methods to estimate muscle mass including
anthropometric measurements, biochemical parameters,
bioelectrical impedance analysis (BIA), and imaging tools
such as dual-energy x-ray absorptiometry, computed
tomography, magnetic resonance imaging, and ultrasound
(US). Among imaging methods, the US seems promising
and has superiority to others in terms of easy, portable,
radiation-free, noninvasive, and repeatable properties. Its
validity and reliability to assess muscle mass have been
studied previously [9,10]. Accordingly, in this study, we
aimed firstly, to compare the age-related loss of muscle
mass by using US in older adults with and without
dementia; secondly to compare sarcopenia diagnosed by
gastrocnemius (GC) muscle thickness by US and skeletal
muscle mass index (SMI) by BIA.
2. Materials and methods
Between October 2019–March 2020 a total of 530
older patients (≥65-year-old) from two geriatric outpatient clinics were included in this cross-sectional
study. After the assessment of exclusion criteria, the
study was concluded with 221 patients. Anthropometric
measurements including weight, height, and waist and hip
circumferences and chronic diseases were recorded. All
patients underwent a comprehensive geriatric assessment.
Patients with deteriorating general conditions, advanced
dementia, pacemaker, prosthesis, severe edema, and
electrolyte imbalance were excluded from the study. This
study was approved by the local ethics committee (E-202138/23.06.2021) and it was performed in accordance with
the ethical standards as laid down in the 1964 Declaration
of Helsinki. All participants gave informed consent.
The diagnosis of dementia was based on the original
National Institute of Aging and Alzheimer’s Association
(NIA-AA) criteria for AD and the major neurocognitive
disorder definition in the Diagnostic and Statistical
Manual of Mental Disorders-V (DSM-V) [11,12].
The BIA measurement was taken using Bodystat
Quadscan 4000 device (FL, USA) in the supine position.
Electrodes were placed on the dorsal surface of the
metacarpophalangeal and metatarsophalangeal joints,
medially between the distal prominences of the radius and
ulna and between the medial and lateral malleoli at the
ankle. The SMI was calculated as described elsewhere [13].
The US evaluations were performed using a 5-12
MHz linear probe (Logiq 200 Pro, and Logiq P5 GE
Medical Systems) by the same geriatricians (GŞA, ÖK).
Measurements were performed unilaterally (dominant
hand side) on the medial head of the GC muscle at the

bulkiest area, in the prone position. Muscle thickness was
determined as the distance between the upper and deeper
aponeurosis with minimal compression.
Diagnosis of sarcopenia was based on definitions from
the EWGSOP2 in 2018. The diagnosis of sarcopenia was
established if low muscle mass (according to either SMI
(<7.4 kg/m2 for females, <9.2 kg/m2 for males) [13] or
sonographic GC muscle thickness (<13 mm for each sex)
was combined with low grip strength (<19 kg for females,
<32 kg for males) [14].
Muscle strength was measured by ‘Grip strength
dynamometer, Grip D produced by Takei/Made in
Japan with the dominant hand, and measurements were
repeated for three times after 10-s intervals and the
maximum handgrip strength value was recorded. Physical
performance was assessed by a 4-meter usual gait speed.
Walking speed ≤0.8 m/s was accepted as low physical
performance.
2.1. Statistical analysis
Statistical analyses were performed using SPSS 21.
Numerical variables are shown as mean ± SD, categorical
variables as N (%). Normal distribution was tested by
Kolmogorov-Smirnov test (if sample size > 50) or ShapiroWilk test (sample size < 50). Continuous variables were
compared by Mann Whitney U or Student’s t-test; while
categorical variables were compared by chi-square or
Fisher’s exact test, where appropriate. Correlations among
demographic and sarcopenia-related parameters were
assessed by Pearson or Spearman correlation coefficients
in each sex. In addition, for predicting the presence of
sarcopenia (either confirmed by SMI by BIA or GC muscle
thickness by US), clinical variables were taken into binary
logistic regression analysis (with backward likelihood ratio
selection). Statistical significance was set at p < 0.05.
3. Results
The frequency of sarcopenia in older adults is shown
in Figure. A total of 21 subjects (9.5%) had sarcopenia
diagnosed by both SMI and GC muscle thickness, 10
subjects (4.5%) had sarcopenia diagnosed by SMI only,
and 20 subjects (9.0%) had sarcopenia diagnosed by GC
muscle thickness only.
A comparison of the clinical characteristics of older
adults with and without dementia is shown in Table. 1.
Among the participants, 46 of them (20.8%) had dementia.
Patients with dementia were older than those without
dementia subjects (p < 0.001). Weight, body mass index
and all the sarcopenia-related parameters (i.e. GC muscle
thickness, SMI, grip strength, and gait speed) were found
to be lower in dementia patients than without (p < 0.01).
The frequency of sarcopenia-diagnosed by GC muscle
thickness- was higher in dementia patients (45.7% vs.
11.4%) than those without dementia subjects (p < 0.001).
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Correlation analyses showed that there were similar/
moderate correlation coefficients between skeletal muscle
mass (SMM) and GC muscle thickness with grip strength
and gait speed values (all p < 0.01) (Table 2). There were
also only moderate correlations between sarcopenia
diagnosed by GC muscle thickness and sarcopenia
diagnosed by SMI (r = 0.625 for males, r = 0.464 for
females, both p < 0.01).
Among 221 older adults, 31 (16 M, 15 F) subjects
(14.0%) had sarcopenia confirmed by SMI, and 41 (13 M,
28 F) subjects (18.6%) had sarcopenia diagnosed by GC

muscle thickness (Table 1). When clinical variables were
taken into binary logistic regression analyses; age (OR
= 1.152 [95% CI: 1.055–1.257], male sex [OR = 13.403
(95% CI: 3.211–55.952)] and weight [OR = 0.840 (95%
CI: 0.788–0.894)] were independently associated with
sarcopenia diagnosed by SMI (all p < 0.01) (Table 3). On
the other hand, age [OR = 1.095 (95% CI: 1.028–1.167)],
weight [OR = 0.918 (95% CI: 0.887–0.950)], and presence
of dementia [OR = 5.109 (95% CI: 2.002–13,033)] were
independently associated with the sarcopenia diagnosed
with GC muscle thickness (all p < 0.01) (Table 4).

Table 1. Comparison of the clinical variables between older adults with/without dementia (N = 221).

Characteristic

Dementia
(N = 46)

No dementia
(N = 175)

p

Age (year)

79.0 ± 7.1

72.6 ± 6.3

<0.001

Sex, male

22 (47.8)

56 (32.0)

0.046

Height (cm)

157.6 ± 9.2

159.5 ± 9.4

0.157

Weight (kg)

68.8 ± 14.0

72.5 ± 13.8

<0.001

BMI (kg/m )

27.8 ± 5.7

28.6 ± 5.8

<0.001

Waist

100.6 ± 16.1

99.6 ± 13.9

<0.001

Hip

104.4 ± 18.8

108.7 ± 11.0

<0.001

Calf

32.8 ± 4.4

35.6 ± 4.5

<0.001

Hypertension

38 (82.6)

113 (64.6)

0.019

DM

15 (32.6)

39 (22.3)

0.147

CAD

7 (15.2)

22 (12.6)

0.636

Hyperlipidemia

19 (41.3)

31 (17.7)

0.001

CRD

3 (6.5)

5 (2.9)

0.218

Hypothyroidism

5 (10.9)

17 (9.7)

0.500

Grip strength (kg)

18.5 ± 7.3

22.5 ± 8.7

<0.001

Low grip strength

39 (84.8)

86 (49.1)

<0.001

Gait speed (m/s)

0.49 ± 0.22

0.92 ± 0.37

<0.001

Slow gait speed

40 (87.0)

78 (44.6)

<0.001

GC (mm)

13.6 ± 3.2

15.8 ± 3.0

<0.001

Low GC MT

24 (52.2)

25 (14.3)

<0.001

SMI (kg/m )

9.3 ± 2.0

9.9 ± 1.8

<0.001

Low SMI

13 (28.3)

21 (12.0)

0.007

Sarcopenia by SMI

13 (28.3)

18 (10.3)

0.002

Sarcopenia by GC MT

21 (45.7)

20 (11.4)

<0.001

2

Circumference (cm)

Comorbidities

2

Data are given as mean ± SD, or N (%).
Statistically significant variables are shown as bold.
N; number, BMI; body mass index, DM; diabetes mellitus, CAD; coronary artery disease, CRD; chronic renal disease, GC;
gastrocnemius muscle thickness, SMI; skeletal muscle mass index, s; second.
* Statistical significance was caused by this value.
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Sarcopenia
SMI

Sarcopenia both

10

No sarcopenia

21

Sarcopenia GC

20
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Figure. The frequency of sarcopenia in the older group (aged ≥65 years). 21 individuals
Figure.
The frequency of sarcopenia in the older group (aged ≥65 years).
Twenty-one
individuals
(9.5%)
according
bothand
skeletal
(9.5%) had sarcopenia
according
to had
both sarcopenia
skeletal muscle
mass indexto(SMI)
gastrocnemius
muscle mass index (SMI) and gastrocnemius (GC) muscle thickness, ten
(GC) muscle
thickness, 10 diagnosed
(4.5%) had sarcopenia
diagnosed
SMI only,
and 20
(9.0%) had
(4.5%)
had sarcopenia
by SMI only,
andbytwenty
(9.0%)
had
sarcopenia
diagnosed
by
GC
muscle
thickness
only.
sarcopenia diagnosed by GC muscle thickness only.

Table 2. Correlations among different sarcopenia diagnoses§ with grip strength and gait speed (N = 221).
Data

SMM

GC MT

Age

Weight

Height

HGS

Gait speed

Males
(N = 78)

SMM

-

0.545**

-0.257*

0.828**

0.511**

0.338**

0.381**

GC MT

0.545**

-

-0.322*

0.478**

0.151

0.369**

0.420**

Females
(N = 143)

SMM

-

0.336**

-0.349**

0.618**

0.588**

0.314**

0.401**

GC MT

0.336**

-

-0.289**

0.263*

0.124

0.365**

0.250*

SMM; skeletal muscle mass, HGS; handgrip strength
GC MT; gastrocnemius muscle thickness
* p < 0.01, ** p < 0.001
§

Table 3. Binary logistic regression analysis for predicting sarcopenia diagnosed by SMI (N = 221).
Dependent variable
Sarcopenia (N = 31)

Independent variable*

Exp (β)

95% CI

P

Age

1.152

1.055-1.257

0.002

Sex (male vs. female)

13.403

3.211-55.952

<0.001

Weight

0.840

0.788-0.894

<0.001

β; standardized coefficients, CI; confidence interval
*Age, sex, weight, height, and presence of comorbidities are included in the analyses.

4. Discussion
This study showed that sarcopenia was more prevalent in
older adults with dementia (in almost half) than without.
Sarcopenia confirmed by GC muscle thickness or SMI had
similar/moderate relations with functional parameters. Of

note, amongst different factors, increased age, having low
body weight, and the presence of dementia (about 5 times)
are independently associated with the risk of sarcopenia
diagnosed with GC muscle thickness (but not with SMI)
in older adults.
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Table 4. Binary logistic regression analysis for predicting sarcopenia diagnosed by GC (N = 221).
Dependent variable
Sarcopenia (N=41)

Independent variable*

Exp (β)

95% CI

P

Age

1.095

1.028–1.167

0.005

Weight

0.918

0.887–0.950

<0.001

Dementia

5.109

2.002–13.033

0.001

β; standardized coefficients, CI; confidence interval
*Age, sex, weight, height, and presence of comorbidities are included in the analyses.

In our study, we have found that dementia is
independently associated with the development of
sarcopenia. This relationship was prominent when binary
logistic regression analyses were performed for sarcopenia
diagnosed with GC muscle thickness. Loss of lean muscle
mass in AD is found to be associated with brain atrophy and
cognition [15]. Sarcopenia characteristics are often present
in dementia patients. The link between these conditions
may be either a consequence of AD pathophysiology
or due to common mechanisms, such as inflammation
[16,17]. Additionally, the presentation of sarcopenia in
these individuals may be due to the reduction in physical
activity levels or presence of malnutrition.
Normally, muscle thickness is positively correlated
with weight and negatively correlated with height, that is,
positively correlated with BMI [18]. Therefore, an increase
in BMI in healthy adults leads to an increase in the muscle
thickness measurements. As the normalized/adjusted cutoff values for GC muscle thickness are not available in the
literature, the use of absolute values (<13 mm for each sex)
may cause some errors. Therefore, having low weight values
seemed to be a risk factor for sarcopenia. Additionally,
since measurements of SMM by BIA were adjusted for
height square, weak/slim subjects (such as nonobese male
older adults) who had low grip strength might have been
misdiagnosed as sarcopenic (overestimated), while those
who are obese but having low grip strength (such as obese
female older adults) might have been wrongly defined as
normal (underestimated) [18]. As male older adults were
taller and had lower body mass index than females and
when SMM is adjusted with the height square males were
misdiagnosed as sarcopenic. Indeed, in our study, as SMM
was moderately to strongly related with weight and height
in the correlation analysis, male older adults were found to
be 13 times more at risk for sarcopenia diagnosed by SMI.
Of course, the interesting thing here is that although
the majority of dementia patients (about 90%) had low
muscle strength and slow walking speed (i.e. frail),
dementia was not found as a risk factor for sarcopenia
when diagnosed by SMI, however male sex was incorrectly
determined as an important risk factor. In fact, this creates
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a disadvantage for the male sex (as having low muscle
mass) since SMM was only adjusted by the height square.
However, since sarcopenia affects muscles rich in type II
(fast-twitch) fibers, measuring the affected muscles’ mass
seems more rationale. In this regard, beside increased age
and having low body weight, we found that presence of
dementia independently increased (about 5 times) the risk
of sarcopenia when diagnosed with GC muscle thickness
in older adults.
We showed that, there were similar but moderate
correlation coefficients between sarcopenia confirmed by
GC muscle thickness and SMI with grip strength and gait
speed values. It has been shown that GC muscle thickness
measured by US predicts low muscle strength better than
SMI measured by BIA [19]. There was a positive correlation
between GC muscle thickness and handgrip strength
in both sexes. Additionally, the authors mentioned that
GC muscle thickness predicts sarcopenia and muscle
strength in sarcopenic patients as well as SMI and other
anthropometric measurements [19]. Recent years, the
use of US in daily practice is rising and it has been shown
that rather than loss of total muscle mass, regional muscle
loss (i.e. volume, cross-sectional area, or thickness) can
be more valuable in the diagnosis of sarcopenia [20].
As it has been mentioned previously, anterior thigh
muscles undergo atrophy earlier with ageing, and this
issue is paramount for the prevention of impairments and
interventions [20]. Although we measured GC muscle
thickness and used absolute values in this study, use of
adjusted anterior thigh muscle thickness could give more
accurate results [21].
The study has several limitations. First of all, it is a
cross-sectional study and it is difficult to conclude that we
could predict sarcopenia with US measures in dementia
patients. While we can only talk about an independent
association. Secondly, the small study population size
limits the generalization of the interpretations.
In conclusion, this study showed that sarcopenia is
highly prevalent (in almost half) in older adults with
dementia. Of note, beside increased age and having
low body weight, presence of dementia independently
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increased (about 5 times) the risk of sarcopenia diagnosed
with GC muscle thickness (but not diagnosed with SMI) in
older adults. Thus, we can evaluate easily and successfully
the loss of (regional) muscle mass in chronic disorders such
as dementia patients by using the US in outpatient clinics.
Further studies in a longitudinal manner with larger

populations are needed to investigate the relationship
between cognitive dysfunction and sarcopenia.
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